0.04
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About IDT Australia
Its shares trade on ASX under the ticker IDT.AX. It has been listed since 22 March 1988. In the fiscal year to 30 June 2026, it reported revenue of A$20.4m and a net loss of A$2.7m. At that date it held total assets of A$34.9m and shareholders' equity of A$19.0m.
IDT Australia Ltd. produces, develops and supplies pharmaceutical products. The company is headquartered in Melbourne, Victoria. The firm's segments include CMAX, Boronia and Corporate/Unallocated. Its CMAX is a clinical trial facility in Adelaide, South Australia. The company has an integrated manufacturing, development and corporate facility at Boronia, Victoria. The firm specializes in manufacture of active pharmaceutical ingredients (API) and finished dose products, including beta lactams; microbiological and analytical testing; clinical packaging, and Phase I and first time in man clinical trials research and pharmacy services. Its IDT Pharma specializes in the development, scale-up and current goods manufacturing practices (cGMP) clinical and commercial manufacture of cytotoxic API and finished drug product. The firm also offers a range of clinical trial labelling, packaging and dispensing services.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 Mar 1988
- Employees
- 156
- Website
- idtaus.com.au ↗
Leadership
Pay as last reported
- Mr. Mark SimariNon-Executive Independent Chairman of the Board
- Mr. Paul McdonaldChief Executive OfficerA$321,786
- Mr. Mahendran VasanthakumarInterim Chief Financial Officer
- Mr. Chris KagiarosHead of People and CultureA$246,924
- Mr. Mark LicciardoCompany Secretary
- Mr. Hugh BurrillNon-Executive Independent DirectorA$70,000
- Dr. Jane RyanNon-Executive Independent DirectorA$29,722
- Mr. Geoffrey SamIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- IDT Australia Ltd possesses several key strengths that contribute to its success in the market. First and foremost, the company has a strong and experienced management team that brings valuable expertise to the table. This allows them to make strategic decisions effectively and navigate the industry with confidence. Additionally, IDT Australia Ltd has a diverse product portfolio that includes innovative pharmaceuticals and biotechnology products. This enables the company to cater to a wide range of customer needs and stay ahead of competitors.
Weaknesses
- Despite its strengths, IDT Australia Ltd also faces certain weaknesses that need to be addressed. One notable weakness is the company's heavy reliance on a limited number of suppliers for raw materials. This puts IDT at risk of potential supply chain disruptions, which may impact production and timely delivery of products. Another weakness is the company's relatively small market share compared to some larger competitors, which limits its bargaining power and hinders expansion opportunities.
Opportunities
- IDT Australia Ltd operates in an industry that presents several growth opportunities. The increasing global demand for pharmaceutical products and biotechnology advancements provides a favorable market for the company to expand its customer base and increase sales. Moreover, the growing importance of research and development in the healthcare sector opens doors for IDT to invest in innovation and develop new, groundbreaking products. Additionally, the company can explore strategic partnerships and collaborations to leverage the expertise and resources of other organizations.
Threats
- IDT Australia Ltd faces certain threats that may pose challenges to its growth and profitability. One significant threat is intense competition from both domestic and international pharmaceutical companies. This requires IDT to continually differentiate itself through product quality, pricing, and marketing strategies to maintain its market position. Another threat is the stringent regulatory environment governing the healthcare industry, which can lead to increased compliance costs and delays in product approvals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.